An estimated 20% of patients taking an antipsychotic medication will develop the iatrogenic disorder tardive dyskinesia (TD), marked by abnormal involuntary movements and imposing a substantial negative impact on patient quality of life and clinical outcomes. In 2017, the first pharmacotherapies for the treatment of TD—the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine—were approved, rendering routine diagnosis and monitoring of TD more essential than ever in order to support timely and effective treatment with these agents. But what do you do once you initiate treatment for TD? In this session, expert faculty will lay out comprehensive follow-up plans that incorporate individualized monitoring and dose adjustment recommendations and strategies to overcome common challenges encountered over the course of care, so you achieve optimal treatment outcomes with your patients.
Supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.